G1 Therapeutics Inc (STU:G1H)
€ 6.39 0 (0%) Market Cap: 339.15 Mil Enterprise Value: 327.68 Mil PE Ratio: 0 PB Ratio: 15.31 GF Score: 32/100

G1 Therapeutics Inc at 38th Annual J.P Morgan Healthcare Conference Transcript

Jan 14, 2020 / 05:30PM GMT
Release Date Price: €22.07 (+3.08%)
Anupam Rama
JP Morgan Chase & Co, Research Division - VP and Analyst

Okay. We'll go ahead and get started. I want to thank everyone for coming. This is the Tuesday morning of the 2020 JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Tessa Romero and Matt Bannon from the team. Our next presenting company is G1 Therapeutics. And speaking on behalf of the company, we have CEO, Mark Velleca. Mark?

Mark A. Velleca
G1 Therapeutics, Inc. - CEO, President & Director

Good morning. Thanks, Anupam, for the introduction. I appreciate the opportunity to share the G1 Therapeutics story with all of you here today in San Francisco. I'd also like to welcome those joining via webcast.

2020 is an important year for G1 as we prepare to file our first NDA for our lead program, trilaciclib. So our safe harbor statement. G1 is advancing 3 investigational therapies. Trilaciclib, rintodestrant and lerociclib. But it's trilaciclib that makes us unique from our peers in the oncology

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot